181 related articles for article (PubMed ID: 19047164)
1. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
2. In vivo structural activity and optimization studies of folate-tubulysin conjugates.
Reddy JA; Dorton R; Dawson A; Vetzel M; Parker N; Nicoson JS; Westrick E; Klein PJ; Wang Y; Vlahov IR; Leamon CP
Mol Pharm; 2009; 6(5):1518-25. PubMed ID: 19630399
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic efficiency of FP-PEA/TAM67 gene complexes via folate receptor-mediated endocytosis in a xenograft mice model.
Arote RB; Hwang SK; Lim HT; Kim TH; Jere D; Jiang HL; Kim YK; Cho MH; Cho CS
Biomaterials; 2010 Mar; 31(8):2435-45. PubMed ID: 20022105
[TBL] [Abstract][Full Text] [Related]
4. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
5. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.
Leamon CP; Reddy JA; Vlahov IR; Dorton R; Bloomfield A; Vetzel M; Klein PJ; Westrick E; Xu LC; Wang Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1151-1160. PubMed ID: 28451831
[TBL] [Abstract][Full Text] [Related]
6. Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice.
Müller C; Reddy JA; Leamon CP; Schibli R
Mol Pharm; 2010 Apr; 7(2):597-604. PubMed ID: 20199053
[TBL] [Abstract][Full Text] [Related]
7. Real time, noninvasive imaging and quantitation of the accumulation of ligand-targeted drugs into receptor-expressing solid tumors.
Vlashi E; Sturgis JE; Thomas M; Low PS
Mol Pharm; 2009; 6(6):1868-75. PubMed ID: 19754150
[TBL] [Abstract][Full Text] [Related]
8. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers.
Dosio F; Milla P; Cattel L
Curr Opin Investig Drugs; 2010 Dec; 11(12):1424-33. PubMed ID: 21154124
[TBL] [Abstract][Full Text] [Related]
9. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast.
Reber J; Struthers H; Betzel T; Hohn A; Schibli R; Müller C
Mol Pharm; 2012 May; 9(5):1213-21. PubMed ID: 22509996
[TBL] [Abstract][Full Text] [Related]
10. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues.
Thomas M; Kularatne SA; Qi L; Kleindl P; Leamon CP; Hansen MJ; Low PS
Ann N Y Acad Sci; 2009 Sep; 1175():32-9. PubMed ID: 19796075
[TBL] [Abstract][Full Text] [Related]
11. Targeting of nanoparticles: folate receptor.
Kularatne SA; Low PS
Methods Mol Biol; 2010; 624():249-65. PubMed ID: 20217601
[TBL] [Abstract][Full Text] [Related]
12. Folate-conjugated micelles and their folate-receptor-mediated endocytosis.
Lu T; Sun J; Chen X; Zhang P; Jing X
Macromol Biosci; 2009 Nov; 9(11):1059-68. PubMed ID: 19688723
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
14. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
15. A molecular receptor targeted, hydroxyapatite nanocrystal based multi-modal contrast agent.
Ashokan A; Menon D; Nair S; Koyakutty M
Biomaterials; 2010 Mar; 31(9):2606-16. PubMed ID: 20035998
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent.
Reddy JA; Nelson M; Dircksen C; Vetzel M; Johnson T; Cross V; Westrick E; Qi L; Hahn S; Santhapuram HK; Parham G; Wang K; Vaughn JF; Felten A; Pugh M; Lu J; Klein P; Vlahov IR; Leamon CP
Sci Rep; 2020 Jul; 10(1):12772. PubMed ID: 32728172
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of folate-based chlorambucil delivery systems for tumor-targeted chemotherapy.
Guaragna A; Chiaviello A; Paolella C; D'Alonzo D; Palumbo G; Palumbo G
Bioconjug Chem; 2012 Jan; 23(1):84-96. PubMed ID: 22121907
[TBL] [Abstract][Full Text] [Related]
18. Combined muta- and semisynthesis: a powerful synthetic hybrid approach to access target specific antitumor agents based on ansamitocin P3.
Taft F; Harmrolfs K; Nickeleit I; Heutling A; Kiene M; Malek N; Sasse F; Kirschning A
Chemistry; 2012 Jan; 18(3):880-6. PubMed ID: 22170289
[TBL] [Abstract][Full Text] [Related]
19. Folate-appended β-cyclodextrin as a promising tumor targeting carrier for antitumor drugs in vitro and in vivo.
Okamatsu A; Motoyama K; Onodera R; Higashi T; Koshigoe T; Shimada Y; Hattori K; Takeuchi T; Arima H
Bioconjug Chem; 2013 Apr; 24(4):724-33. PubMed ID: 23458386
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative.
Abu Ajaj K; El-Abadla N; Welker P; Azab S; Zeisig R; Fichtner I; Kratz F
Eur J Cancer; 2012 Sep; 48(13):2054-65. PubMed ID: 21937219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
